Dual GIP / GLP-1 receptor agonist
Tirzepatide
A synthetic, lipidated peptide that activates GIP and GLP-1 receptors.
Why it is discussed
Diabetes treatment and chronic weight management
Tirzepatide activates two incretin pathways and is discussed for its effects on glucose control, appetite, and body weight. Approved uses, contraindications, and strengths are product-specific; a research vial is not equivalent to an authorized medicine.
What it is
One peptide acting at two hormone receptors.
Tirzepatide is a modified peptide that activates receptors for GIP and GLP-1. These are incretin hormones: signals involved in coordinating the body's response to food. It is one molecule with two receptor targets, not a mixture of two medicines. An attached fatty-acid group promotes albumin binding, helping prolong its presence in circulation.
How it works
Coordinated signals for blood sugar and food intake.
In pancreatic beta cells, receptor activation increases internal signaling that supports insulin release when glucose is elevated. Tirzepatide also affects glucagon secretion, food intake, and gastric emptying. These actions help explain its metabolic effects; they do not make it insulin or a direct fat-dissolving agent.
The two receptor actions are not equal halves. Laboratory studies found different activity at GIP and GLP-1 receptors and different patterns of downstream signaling. Receptor pharmacology helps explain how a molecule works, but it cannot by itself predict an individual's response.
Glucose-dependent action does not eliminate low-blood-sugar risk, particularly alongside insulin or certain diabetes medicines. Product-specific absorption, benefits, and risks cannot be transferred to an unverified preparation bearing the same name.
Scientific / evidence sources
Evidence at a glance
What is established—and what is not.
Product-specific randomized trials and regulatory review
Controlled human trials support specific authorized tirzepatide products for defined metabolic indications and populations.
Clinical findings do not establish the identity, quality, equivalence, or labeled quantity of a research vial carrying the ingredient name.
Regulatory status
Canada and the United States are checked separately.
Authorized prescription products appear in Health Canada’s Drug Product Database.
FDA-approved products exist; approval applies to specific products and labels.
Regulatory status describes product authorization and relevant regulatory context. It is not a complete legal opinion about possession, importation, prescribing, sale, or professional practice.
If you are reviewing a product report
The molecule profile and the testing report answer different questions.
This page summarizes evidence and regulatory context. A laboratory report may address identity, purity, or quantity for one submitted sample; it does not transfer clinical evidence or product authorization.